Merck to Hold Investor Briefing Featuring Organon on May 3
27 Abril 2021 - 7:47AM
Business Wire
Registration and Meeting Details Available
on Microsite
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today announced that members of Organon management will
host a virtual investor event where they will present the Organon
business strategy, opportunities for growth and financial outlook,
followed by a question and answer session on Monday, May 3 at 10:00
am EDT. The event will last approximately two hours fifteen minutes
and viewers are encouraged to pre-register at
https://www.merck.com/events/organon-co-investor-day/.
Investors, analysts, members of the media and the general public
are invited to register and watch a webcast of the presentation at
https://www.merck.com/events/organon-co-investor-day/ or listen-in
to the audio-only teleconference with the opportunity to ask
questions by dialing 1-844-340-4759 or internationally at
1-412-717-9615.
Additional Resources
Investors, media and general public are invited to learn more
about the pending spinoff leading up to the Investor Day by
accessing resources, including speaker biographies and Frequently
Asked Questions and answers by visiting
https://www.merck.com/events/organon-co-investor-day/.
About Organon
Organon will be a global healthcare company formed through a
spinoff from Merck to focus on improving the health of women
throughout their lives. It will have a portfolio of more than 60
established medicines that address an entire spectrum of conditions
women face and other medical needs. Led by the growing reproductive
health portfolio including patent-protected NEXPLANON (etonogestrel
implant), coupled with an expanding biosimilars business and stable
franchise of established medicines, Organon’s products produce
strong cash flows that will support investments in future growth
opportunities in women’s health, including business development. In
addition, Organon will pursue opportunities to partner with
biopharmaceutical innovators looking to commercialize their
products by leveraging its scale and presence in fast growing
international markets.
Organon is expected to have a global footprint with significant
scale and geographic reach, world-class commercial capabilities,
and approximately 10,000 employees with headquarters located in
Jersey City, New Jersey.
About Merck
For 130 years, Merck, known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases in
pursuit of our mission to save and improve lives. We demonstrate
our commitment to patients and population health by increasing
access to health care through far-reaching policies, programs and
partnerships. Today, Merck continues to be at the forefront of
research to prevent and treat diseases that threaten people and
animals – including cancer, infectious diseases such as HIV and
Ebola, and emerging animal diseases – as we aspire to be the
premier research-intensive biopharmaceutical company in the world.
For more information, visit www.merck.com and connect with us on
Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Examples of
forward-looking statements include statements with respect to the
company’s plans to spinoff certain of its businesses into an
independent company, the timing and structure of such spinoff, the
characteristics of the business to be separated, the expected
benefits of the spinoff to the company and the expected effect on
the company’s dividends. These statements are based upon the
current beliefs and expectations of the company’s management and
are subject to significant risks and uncertainties. There can be no
guarantees with respect to whether the proposed spinoff will be
completed on the proposed timetable or at all. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to,
uncertainties as to the timing of the proposed spinoff;
uncertainties as to the status of any required regulatory
approvals; the possibility that various conditions to the
consummation of the spinoff may not be satisfied; the effects of
disruption from the transactions contemplated in connection with
the spinoff; general industry conditions and competition; general
economic factors, including interest rate and currency exchange
rate fluctuations; the impact of pharmaceutical industry regulation
and health care legislation in the United States and
internationally; the impact of the global outbreak of novel
coronavirus disease (COVID-19); global trends toward health care
cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; the company’s
ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the
effectiveness of the company’s patents and other protections for
innovative products; and the exposure to litigation, including
patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2020
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210427005353/en/
Media Contacts: Patrick Ryan (973) 275-7075
Investor Contacts: Peter Dannenbaum (908) 740-1037
Courtney Ronaldo (908) 740-6132
Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024